Latest filing published 17 Jun 2020 for Rein Therapeutics, Inc., €6,241.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +3.4%Entry US$23.20 · Close at T+365 US$24.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Reinhard J. Ambros: trading record in brief
Reinhard J. Ambros discloses dealings in Rein Therapeutics, Inc. to SEC (Form 4). In total, 3 filings cover trades dated from 5 July 2017 to 15 June 2020.
No open-market sale appears; the market trades are 2 purchases worth €3.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2020 alone, the filings show 1 purchase and no sales.
Most recently, on 17 June 2020, the filings show an open-market purchase worth €6,241 in Rein Therapeutics, Inc. Most trades are made public on the day they happen. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Reinhard J. Ambros
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,800 shares@ US$1.22100.0% of flowCommon StockSEC:0000899243-20-016859:0Canonical exit: 13 Sept 2020 (T+90)
- 2,277,515 sharesCommon StockSEC:0000899243-17-017853:0
- 266,667 shares@ US$15.00Common StockSEC:0000899243-17-017853:1Canonical exit: 3 Oct 2017 (T+90)
3 of 3 declarations
